KGX101 is named as an intervention in 2 current clinical trials in our China and Australia registers. 1 is recruiting patients now. All registered phases are Phase 1. The lead sponsor is Kangabio AUSTRALIA LTD PTY. The most-studied condition is Advanced or Metastatic Solid Tumors.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
NCT07260305 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors
|
Phase 1 | Recruiting | Kangabio AUSTRALIA LTD PTY | China |
|
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
NCT06074497 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors
|
Phase 1 | Active, closed | Kangabio AUSTRALIA LTD PTY | Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Kangabio AUSTRALIA LTD PTY | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Australia | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Australia registers name KGX101 as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Kangabio AUSTRALIA LTD PTY. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how KGX101 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how KGX101 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists KGX101 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.